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ABSTRACT  
Background: Chronic kidney disease causes progressive loss of function which gradually occur overtime leading to decrease in GFR levels 
leading to dysfunction of renal system. Hypertension is found to be intermingled cause and overlapping complication in CKD. I t is important to 
intervene the progression by controlling the blood pressure to prevent kidney failure by administration of anti-hypertensive. Objectives: To 
study current trends in anti-hypertensive prescription pattern in CKD patient and to evaluate the concurrent patterns are in adherence 
according to the guidelines mentioned.  Methods: Prospective observational study was undertaken in patients who were satisfying the 
inclusion criteria and was enrolled into the study conducted for a 6months period in a tertiary care hospital in Bangalore. Results: 150 CKD 
patients were examined out of which 72% prevalence seen in males compared to females 28%. Dual drug therapy was most preferred 
combination seen in 48% of the prescriptions. CCB was the most preferred class of drug and least preferred class of drug was ACE. More than 
85% deviation from JNC-8 was seen. 20% of mono-therapy was found in adherence to JNC-8. Conclusion: A 15% adherence to JNC-8 guidelines 
was observed in the treatment indicating need for clinical pharmacist who play vital role in management of CKD by adherence to JNC-8 to 
ensure safety, efficacy and rationality. 
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INTRODUCTION 
Chronic kidney disease leads to progressive loss of renal 
function which concomitant on the elevated blood pressure 
which is managed by administration of Anti-hypertensives. 
So the main objective of the study is to assess the drug 
prescription pattern of anti-hypertensive in chronic kidney 
disease considering the adherence to the JNC-81. According 
to JNC-8 patients of any age with diabetes or CKD have a goal 
of less than 140 mmHg systolic and less than 90 mmHg 
diastolic. The focus of the JNC-8 is to target on the blood 
pressure values. However, it also provides recommendations 
to promote the safer use of specific anti-hypertensive 
agents2. There is deviation from the regular therapy of ACE 
inhibitors and ARBs, other combinations of the 4 agents that 
can be administered to achieve the ideal goal of blood 
pressure is also recommended. ACE inhibitors or ARBs are 
an essential part of hypertensive management in patients up 
to the age of 75years with CKD, though currently patients 
with greater than the age of 75years with CKD there is no 
authentication supporting renin-angiotensin system 
inhibitor treatment. While ACE inhibitors or ARBs are been 
used, CCBs and Thiazide Diuretics can also be considered3. 
MATERIALS AND METHODS 
The study was a prospective observational study conducted 
for 6 months period to assess prescribing pattern of anti-
hypertensive in chronic kidney disease was carried out at a 
tertiary care hospital in Bangalore. The study was carried out 
on both inpatients and outpatients of the tertiary care 
hospital, who were currently diagnosed with chronic kidney 
disease along with hypertension. Pediatric patients, pregnant 
patients and psychiatric patients were excluded from this 
study. 
All necessary and relevant information were collected from 
patient case sheet, laboratory data report and treatment 
chart. A separate data entry format for incorporating 
patient’s details was designed. The format included the 
details such as Name, Age, Gender, IP number, Data of 
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admission, Date of discharge, Patient medical history, 
Medication history, Laboratory investigation and Treatment 
chart. 
Ethical clearance was obtained for the protocol of the 
present study which was approved by the ethical committee 
of Aditya Bangalore Institute for Pharmacy Education and 
Research and informed consent was agreed by Nephrology 
Department at the tertiary care hospital,  
Statistical Analysis was done by data entered in MS Excel 
2007 and analyzed. Descriptive statistics was expressed in 
terms of actual numbers and percentage was used for data 
analysis. 
RESULTS 
During the 6month period based on the inclusion and 
exclusion criteria 150 prescriptions were collected from the 
tertiary care hospital. The demographic characteristics of 
150 patients are depicted in Table 1. 
 
Table 1: Prescriptions observations 
Particulars  Numbers  Percentage 
I. Gender distribution    
Number of males patients 107 72.33% 
Number of males patients 43 .28.66% 
II. Based on Age Males Females Males Females 
20-29 4 0 3.7% 0 
30-39 11 4 10.28% 9.3% 
40-49 12 7 11.21% 16.27% 
50-59 29 14 27.10% 32.55% 
60-69 36 14 33.64% 32.55% 
70-79 11 4 10.28% 9.3% 
80-89 4 0 3.7% 0 
III. Based on co-morbidity of Diabetes mellitus along 
with HTN and CKD 
Males Females Males Females 
Diabetic 61 29 57% 67.44% 
Non-Diabetic 46 17 42.99% 39.53% 
IV. Type of Therapy    
Mono therapy 40 26.66% 
Dual Therapy  72 48% 
Triple Therapy  22 14.66% 
Quadruple Therapy 11 8.66% 
Other (more than 4) 3 2% 
 
1. Monotherapy of Anti-hypertensive Drug 
Out of the 40 Prescriptions (26.66%)  had monotherapy. Out 
of monotherapy treatment given to patients in the study 
(67.5%) were given calcium channel blockers followed by 
7.5% Diuretics and Alpha blockers respectively. 
 
 
Figure 1: Drugs in Monotheraphy 
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2. Dual therapy of Anti-hypertensives 
Out of the 48% of dual therapy treatment given to the 
patients in the study; 27.7% were treated with CCB+Beta 
blockers, CCB+Central sympatholytic (20.08%) and 
CCB+[Alpha+Beta blockers](18.05%) respectively which 
was found in the prescriptions. 
 
Table 2: Dual Therapy of Anti-hypertensive. 
CLASS OF DRUG NO OF PRESCRIPTION PERCENTAGE 
CCB+ APHA+ BETA BLOCKER 4 5.55% 
 CCB+ DIURETIC 6 8.33% 
CCB+ ACE 2 2.77% 
CCB+ BETA BLOCKER 20 27.77% 
CCB + APHA+ BETA BLOCKER 13 18.05% 
CCB+ CENTRAL SYMPATHOLYTIC 15 20.8% 
DIURETIC+ BETA BLOCKER 3 4.16% 
DIURETIC+ APHA+ BETA BLOCKER 3 2.77% 
DIURETIC+ DIURETIC 1 1.3% 
ALPHA BLOCKER+ BETA BLOCKER 2 2.77% 
CENTRAL SYMPATHOLYTIC+ APHA+ BETA BLOCKER  1.3% 
CENTRAL SYMPATHOLYTIC+ ALPHA BLOCKER 1 1.3% 
BETA BLOCKER + ARB 1 1.3% 
 
 
3. Triple therapy of Anti-hypertensive 
Out of the 14.66% of Triple therapy treatment given to 
patients in the study it was found that 31.8% were given 
CCB +Beta blockers+ Alpha blocker and CCB + Diuretic +Beta 
blockers respectively. 
 
Table 3: Triple Therapy of Anti-hypertensive. 
CLASS OF DRUG NO PERCENTAGE 
CCB+ APHA BLOCKER + BETA BLOCKER 7 31.8% 
 CCB+ DIURETIC+ APHA BLOCKER 2 9.09% 
CCB+ CENTRAL SYMPATHOLYTIC+ APHA BLOCKER 2 9.09% 
CALCIUM CHANNEL +DIURETIC+ BETA BLOCKER 5 22.72% 
CALCIUM CHANNEL + CALCIUM CHANNEL +DIURETIC 1 4.54% 
CCB+ CENTRAL SYMPATHOLYTIC+ DIURETIC 2 9.09% 
CCB +CENTRAL SYMPATHOLYTIC+ BETA BLOCKER 2 9.09% 
CCB +CENTRAL SYMPATHOLYTIC+ ALPHA+BETA BLOCKER 1 4.54% 
CCB +CENTRAL SYMPATHOLYTIC+ARB 1 4.54% 
 APHA BLOCKER + BETA BLOCKER+ DIURETIC 2 9.09% 
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4. Quadruple therapy of Anti-hypertensive 
Out of the 8.66% of Quadruple therapy treatment given to 
the patients in the study it was found that 30.76% were 
given CCB+Beta blockers+ Alpha blocker + Central 
Symphatholytic.
 
Table 4: Quadruple Therapy of Anti-hypertensive. 
CLASS OF DRUG NO OF PRESCRIPTION PERCENTAGE 
CCB +CENTRAL SYMPATHOLYTIC+ ALPHA BLOCKER +BETA BLOCKER 4 30.76% 
CCB +CENTRAL SYMPATHOLYTIC+BETA BLOCKER+ DIURETIC 1 7.69% 
CCB +CENTRAL SYMPATHOLYTIC+ARB+ALPHA BLOCKER 2 15.38% 
CCB +APHA BLOCKER + BETA BLOCKER+ DIURETIC 2 15.38% 
CCB +CENTRAL SYMPATHOLYTIC+ ALPHA BLOCKER +APHA BLOCKER 2 15.38% 
CCB +APHA + BETA BLOCKER+ DIURETIC+ CENTRAL SYMPATHOLYTIC 1 7.69% 
 
5. Others 
In this therapy more than four drug combinations of Anti-
hypertensives were used in 3 prescriptions it was found that 
in 1 prescription CCB  +Beta blockers+ Alpha blocker + 
Central Symphatholytic+ Diuretics was prescribed and 
CCB+Beta blockers+ Alpha blocker + ARB+ Diuretic in other 
2  prescriptions containing more than four anti-
hypertensives. 
 
Figure 2: Others (more than 4). 
6. Different class of Prescription 
In management of hypertension in CKD patient with 
antihypertensives  in 150 prescription the most preferred 
class of drugs was CCB (Calcium channel blocker)which was 
found in 120 prescriptions followed by Beta blockers in 53 
prescription. 
Table 5: Different class of Anti-hypertensive 
NAME OF PATIENT NO OF PRESCRIPTION 
CALCIUM CHANNEL BLOCKER 120 
APHA BLOCKER 39 
ALPHA+BETA BLOCKER 12 
BETA BLOCKER 53 
DIURETIC  26 
CENTRAL SYMPHATHOLYTIC 30 
ACE 2 
ARB 7 
 
 
 
 
7. Calcium Channel Blocker 
In 150 prescription charts assessed most frequently used 
class of drug was calcium channel blockers which were 
found in 120 prescriptions: 
Table 6: Calcium Channel Blockers in Prescription. 
NAME OF DRUG NO PERCENTAGE 
AMLODEPINE 27 22.5% 
NIFEDEPINE 49 40.83% 
CLINIDIPINE 42 35% 
OTHER 2 1.6% 
Out of 120 prescription having CCB (40.83%) have used 
Nifedepine followed by Amlodepine (22.5%), Clinidepine 
(35%). 
8. Beta Blocker 
In 150 prescription charts assessed most frequently used 
class of drug was beta blockers which were found in 53 
prescriptions: 
Table 7: Beta Blockers in Prescription. 
NAME OF 
DRUG 
NO PERCENTAGE 
NEBIVOLOL 8 15.08% 
METOPROLOL 37 69.81% 
BISOPROLOL 8 15.08% 
Out of 53 prescriptions having Beta Blocker Metoprolol was 
the most frequently used Beta blocker in (69.81%) followed 
by Bisoprolol and Nebivolol (15.08%) in 8 prescriptions 
each. 
9. Different drugs of Prescription 
Out of all prescription obtained from the 150 cases that was 
collected; the most frequently prescribed drug were 
Nifedipine(49) followed by Clinidipine(42), Prazosin(38), 
Metoprolol(37),  Clonidine(30), Amlodepine(27) 
respectively. 
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Table 8: Drug in different prescription 
Name of Drug No of Prescription 
Nifedipine 49 
Clinidipine 42 
Prazosin 38 
Metoprolol 37 
Clonidine 30 
Amlodepine  27 
Furosemide 13 
Torsemide  12 
Carvedilol 12 
Nebivolol 8 
Bisoprolol  8 
Telmisartan  3 
Losartan 3 
Enalapril 2 
Others  6 
 
 
Figure 3: Different types of Drugs. 
 
10. Prescription comparison with JNC-8 
According to JNC-8 patients with CKD +HTN +Diabetes 
should be given ACE/ARB/CCB or Diuretic; out of 90 
prescriptions under this category adherence to JNC- 8   was 
seen only in 21 prescriptions. In case of CKD +HTN ACE or 
ARB should be given and out of 60 prescriptions under this 
category adherence to JNC- 8 was seen only in 1 
prescription.
 
Table 9: Drug Comparison with JNC-8. 
Comorbidity  Drugs According to 
JNC-8 
Total Number of 
Prescrpition 
Prescription 
Adherance to JNC-8 
Prescription Non-
Adherance to JNC-8 
CKD+HTN+ 
DIABETES 
ACE/ARB/CCB 
Diuretic 
90 21 69 
CKD+HTN ACE/ARB 60 1 59 
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11. Therapy Based Adherences to JNC-8 
The therapy based Adherence to JNC-8 guidelines showed adherence only in case of Monotherapy(19)  and Dual Therapy (2) 
prescriptions. 
Table 10: Therapy Comparison with JNC-8. 
Therapy Total Prescription Prescription Adherence to 
JNC-8 
Prescription Non-
Adherence to JNC-8 
Mono Therapy 40 19 21 
Dual Therapy 72 2 70 
Triple Therapy 22 0 22 
Quadruple Therapy 13 0 13 
Others 3 0 3 
 
12. Compliance to JNC-8 
The overall adherence of all the prescriptions to JNC-8 guideline in the study was found to be 14.6% which indicate irrationality 
in the prescribing pattern. 
Table 11: Compliance with JNC-8. 
Prescription Status No of Prescription % of Prescription 
Prescription Adherence to JNC-8 22 14.6 % 
Prescription Non-Adherence to JNC-8 128 85.3% 
 
 
Figure 4: Compliance to JNC-8 
 
DISCCUSION  
The study involved 150 CKD patients with HTN to assess the 
prescription pattern of anti-hypertensive found that males of 
age group (60-69years) and (50-59years) are more prone to 
CKD than females this result is similar to the study 
conducted by Neethu Joseph et al.4 depicts 72% of patients 
were male compared to 28% female and a similar result was 
found from the study conducted by Pavitra RY et al. 5. In the 
current study 60% of patients had co-morbidity of DM-2 
which is supported by the study of Sharminder Kaur et al.6 
and Kalpana Bharani et al.7  which showed DM-2 as major 
co-morbidity which was observed in the patients. In the 
present study most of the patients were given multi-drugs 
therapy this result is supported by another study by Ashok 
Kumar Malpani et al.8 that potrayed dual therapy in 78% of 
prescription but differ from the study performed by D.Giri 
Rajasekhar et al. 9 which shows monotherapy as most 
preferred type of therapy. In the present study most 
preferred class of drugs was CCB which is supported with 
the study done by Alwyn p Saju et al.10 and Bhanu Priya B et 
al.11 who found the similar result. The present study 
concludes 85% deviation from JNC-8 guideline which is 
similar to the non adherence to JNC-8 guidelines study 
conducted by Sivasakti Raju et al.12 potrayed only 28 % of 
overall adherence to JNC-8 guidelines confirming physician’s 
non adherence to prescribing pattern in the clinical step 
confirming need of clinical pharmacist in each department 
and to make the physician aware which will help to improve 
adherence to new guidelines in clinical setting. 
CONCLUSION 
The study concluded that the treatment of HTN helps to 
reduce cardiovascular risk associated with the progression 
of CKD and mortality rate. Medical prescriptions were 
assessed to find that males of age group (60-69 years) and 
(50-59 years) are more prone to CKD than the female 
patients. In this study co-morbidity of DM-2 along with HTN 
and CKD was seen more prevalent in female (60%) 
compared to males (57%). In multi-drug therapy dual 
PRESCRIPTION ADHERANCE TO JNC-8
PRESCRIPTION NON ADHERANCE TO JNC-8
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therapy was the most preferred among the other multi-drug 
therapy. The most widely preferred class after assessing all 
of the individual prescription was CCB and ARB were the 
least preferred. According to the results study concludes that 
there was deviation from JNC-8 guidelines (85%) indicating 
non adherence of the physician to the guideline, 20% of 
monotherapy were found to have adherence to JNC-8 
guidelines. No prescriptions contain ARB +ACE combination 
and only 2.5 % of dual therapy prescriptions were found to 
have adhered to JNC-8 guidelines. The study concludes the 
need of clinical pharmacist who plays a vital role in 
management of CKD by adherence to JNC -8 guidelines to 
ensure safety, efficacy and rationality. 
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